{ "items": [ "\n\n
\n \n 15 February 2017\n \n
\n\n \n \n \n\n \n \n \nA new call for Medical Research Council (MRC) Confidence in Concept funding has just been launched as part of the Tropical Infectious Disease Consortium (Jenner Institute, London School of Hygiene & Tropical Medicine, Liverpool School of Tropical Medicine, and Public Health England).
\n \n\n\n \n 15 February 2017\n \n
\n\n \n \n \n\n \n \n \nA new partnership has been formed between European and African researchers to develop an AIDS vaccine that can be used to prevent infection with different strains of HIV worldwide. Led by Professor Tom\u00e1\u0161 Hanke at the Jenner Institute, the Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT) will evaluate a new vaccine that triggers the body to produce specialised immune cells called T-cells, which will be trialled at four sites in Kenya, Uganda and Zambia.
\n \n\n\n \n 9 February 2017\n \n
\n\n \n \n \n\n \n \n \nUniversity of Oxford/University of Cape Town PhD Exchange Programme: Applications are open for the Newton/RCUK PhD partnership scheme for PhD students within medical sciences. There is an opportunity for 8 University of Oxford DPhil students to visit the University of Cape Town on a 4 month exchange visit, with an equivalent opportunity for University of Cape Town PhD students to visit the University of Oxford. The scheme covers the costs of the exchange visits, a stipend, a contribution to research and bench fees or equivalent and additional partnering activities.
\n \n\n\n \n 2 February 2017\n \n
\n\n \n \n \n\n \n \n \nThe \u2018Vaccinology in Africa\u2019 Master\u2019s level course is now open to applications from students, researchers and professionals resident in East Africa. 40 bursaries are available for this fully funded course which covers the main aspects of human and veterinary vaccinology, the vaccine development process, biomanufacturing, clinical trials, regulatory and ethical issues, highlighting human and veterinary links and synergies. The course is jointly organised by the host institution, MUII-Plus (Makerere University-UVRI Centre of Excellence for Infection & Immunity Research and Training) in Entebbe, Uganda, and the Jenner Institute, University of Oxford.
\n \n\n\n \n 20 January 2017\n \n
\n\n \n \n \n\n \n \n \nScientists have named three relatively little-known diseases they think could cause the next global health emergency. A coalition of governments and charities has committed $460m to speed up vaccine development for MERS (Middle East Respiratory Syndrome), Lassa fever and Nipah virus. At the Jenner Institute, scientists are developing vaccines for all three of the viruses. Their MERS vaccine candidate is currently at the most advanced stage worldwide. It is expected that it will be trialled in humans by the end of the year.
\n \n\n\n \n 21 November 2016\n \n
\n\n \n \n \n\n \n \n \nJenner Institute scientists, Dr Lynda Coughlan and Prof Adrian Hill have been awarded the 2016 British Medical Association HC Roscoe grant for a research project which aims to develop improved vaccines for influenza.
\n \n\n\n \n 21 November 2016\n \n
\n\n \n \n \n\n \n \n \nUK researchers creating new vaccines for epidemic diseases such as Zika and Ebola are among the winners of \u00a322 million of funding, announced by the Department of Health today. These projects will be the first to benefit from the UK Vaccine Network, a \u00a3120 million fund launched last year to support Britain\u2019s world-leading role fighting deadly diseases. The network brings together leading figures from industry, academia and philanthropy, including the Jenner Institute, University of Oxford, the Wellcome Trust, and GlaxoSmithKline (GSK).
\n \n\n\n \n 4 November 2016\n \n
\n\n \n \n \n\n \n \n \nIn this issue, there is a particular highlight on Outbreak Pathogens. In the past months, Jenner researchers have received major funding to manufacture and clinically develop vaccine candidates against several outbreak pathogens of international concern: Zika, Chikungunya, MERS and Rift Valley Fever. Recently, the Jenner Institute has also initiated research programmes on vaccines against non-communicable diseases such as prostate cancer and psoriasis, and Prof Lucy Dorrell\u2019s group is utilizing the Jenner Institute\u2019s viral vector prime-boost platform to deliver therapeutic vaccine against cervical pre-cancer.
\n \n\n\n \n 28 September 2016\n \n
\n\n \n \n \n\n \n \n \n'Going Viral' is the first in a new series of audio podcasts. This episode, featuring Dr Sandy Douglas from the Jenner Institute, explores how we learn to use viruses to our own advantage, in fighting them with vaccines as well as harnessing them for use in understanding how the brain is connected.
\n \n\n\n \n 28 September 2016\n \n
\n\n \n \n \n\n \n \n \nThe University of Oxford's Professor Sir Peter Ratcliffe has won the Albert Lasker Basic Medical Research Award, one of the most prestigious prizes in medicine, for his work understanding the mechanisms by which cells sense and signal hypoxia (low oxygen levels). Hypoxia is an important component of many human diseases including cancer, heart disease, stroke, vascular disease, and anaemia.
\n \n\n\n \n 7 September 2016\n \n
\n\n \n \n \n\n \n \n \n17-20 Oct: Clinical Vaccine Development and Biomanufacturing\r\n\r\nFrom pre-clinical testing to field trials - development and manufacture of vaccines, immunogenicity and vaccine testing in Phases I to IV .\r\n21-25 Nov: Human and Veterinary Vaccinology\r\n\r\n5 day Master's level course providing an overview of all aspects of human and veterinary vaccinology - from Edward Jenner to modern day vaccines.
\n \n\n\n \n 19 July 2016\n \n
\n\n \n \n \n\n \n \n \nWhile HIV is no longer the death sentence it once was, we are yet to defeat it entirely. However, a new study from Oxford University offers hope that HIV will eventually have nowhere to hide. Tom Calver spoke to Professor Lucy Dorrell (Jenner Investigator) about her work on clearing HIV from the body.
\n \n\n\n \n 19 July 2016\n \n
\n\n \n \n \n\n \n \n \nCONACyT will fund through its 2016 \u201cFrontiers of Science\u201d call a project submitted by Dr H\u00e9ctor Vivanco Cid of Universidad Veracruzana in collaboration with Prof Reyes-Sandoval Group, The Jenner Institute, Nuffield Department of Medicine. The study will take place in in the sate of Veracruz, which has had the highest numbers of cases of dengue fever and dengue haemorrhagic fever in Mexico in recent years, and the highest number of hospitalisations due to this disease. It is expected that chikungunya and zika viruses will become endemic in this region as well.
\n \n\n\n \n 3 June 2016\n \n
\n\n \n \n \n\n \n \n \n(CNN) As director of the Jenner Institute, Hill is creating a well-crafted \"potion\" of ingredients which, when combined inside a vaccine, could prepare our immune system to attack biological invaders. His formulation could one day form the foundation to protect humans from a range of diseases including malaria, HIV and tuberculosis. It's being harnessed to design a new class of vaccine, unlike any other in use today, with an end goal of disease elimination. \"This is being assessed widely for use in cancer, Hepatitis C, and we've used it in Ebola and HIV,\" says Hill. \"There are 8 different diseases where [this] approach is in clinical trial.\"
\n \n\n\n \n 25 May 2016\n \n
\n\n \n \n \n\n \n \n \nA team led by Oxford University has identified genes that make certain children more susceptible to invasive bacterial infections by performing a large genome-wide association study in African children. Dr Anna Rautanen from Adrian Hill's research group at the Wellcome Trust Centre for Human Genetics, said: 'Critically, the genetic variants we have identified carry a doubled risk of developing bacteraemia when infected with the Streptococcus pneumoniae bacteria. This discovery therefore provides clues in the pressing search for new ways to target the disease.'
\n \n\n\n \n 16 May 2016\n \n
\n\n \n \n \n\n \n \n \nRed tape is hampering scientists from developing groundbreaking GM vaccines, it is claimed. Adrian Hill, of Oxford University, said that this was holding back research. \u201cBecause the vaccine is technically a GM organism, if we\u2019re going to vaccinate someone in our clinic we need special permission, not to protect the person from the dangers of the vaccine but to protect from the potential risks of that microbe getting out and contaminating the environment,\u201d he said. This was despite the fact, he added, that it would not survive.
\n \n\n\n \n 11 May 2016\n \n
\n\n \n \n \n\n \n \n \nOxford spin out company Vaccitech has launched today with \u00a310m seed investment to develop a universal flu vaccine already showing promise in clinical trials. Vaccitech has raised \u00a310m from investment company Oxford Sciences Innovation to take a number of vaccines through clinical trials. Vaccitech\u2019s lead product is a \u201cuniversal\u201d flu vaccine which would work against all varieties of the virus. \u201cWe\u2019ve targeted two proteins inside the virus which do not change, even as the virus mutates the proteins on its surface,\u201d explains Adrian Hill, director of the Jenner Institute. Vaccitech is also working on vaccines to fight cancer by turning the immune system against the disease.\r\n\r\nThe Financial Times: Oxford biotech deals highlight stature of UK university spinouts.
\n \n\n\n \n 11 May 2016\n \n
\n\n \n \n \n\n \n \n \nIn 2014/2015, 39 women scientists working mainly in the Medical Sciences Division at the University of Oxford were interviewed with the aim of providing support to women making career decisions, by offering them the opportunity to explore a broad range of experiences shared by other women through video interviews. The women talked about many issues, including the culture of science, publishing, obtaining fellowship funding, having a mentor and Athena SWAN. Four Jenner Investigators were among those interviewed, Helen McShane, Ellie Barnes, Lucy Dorrell and Seph Borrow.
\n \n\n\n \n 3 May 2016\n \n
\n\n \n \n \n\n \n \n \nOn 25th April, a group of leading research networks and groups in Oxford presented to the public their latest work to combat malaria. Philippe Gu\u00e9rin (WWARN) presented alongside Dominic Kwiatkowski (MalariaGen), Katherine Battle (Malaria Atlas Project), Nick White (MORU) and Sumi Biswas (Jenner Institute), discussing their innovative research and multi-disciplinary collaborations in malaria.
\n \n\n\n \n 29 April 2016\n \n
\n\n \n \n \n\n \n \n \nThe 24 - 30 April is World Immunisation Week with the focus of this year\u2019s WHO campaign is \u201cClose the immunisation gap\u201d. NDM and Paediatrics spoke to Professor Calman MacLennan, Professor of Vaccine Immunology (University of Birmingham) and Jenner Investigator (Oxford), and Dr Manish Sadarangani Clinical Lecturer and Honorary Consultant in Paediatric Infectious Diseases and Immunology at The Children\u2019s Hospital, Oxford about vaccinations and how we can \u201cclose the gap\u201d and get more people vaccinated to prevent deadly diseases.
\n \n\n